137 results
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of motixafortide for patients with sickle cell disease and pancreatic cancer. In addition, we have an off-strategy, legacy therapeutic product called BL-5010 … candidates that we believe exhibit a high probability of therapeutic and commercial success. Our strategy includes commercializing our therapeutic
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
or significant changes in a licensee’s business strategy may adversely affect the licensee’s willingness or ability to complete its obligations under any … to terminate the Agalimmune Development Agreement effective March 15, 2024.
An important element of our strategy is maintaining relationships
F-3
BLRX
Bioline Rx Ltd
29 Dec 23
Shelf registration (foreign)
4:15pm
in development for solid tumors. In addition, we have an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. We … for marketing or commercial sale. Our strategy includes commercializing our therapeutic candidates by way of out-licensing arrangements
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
. In addition, we have an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. We have generated our pipeline … sale. Our strategy includes commercializing our therapeutic candidates by way of out-licensing arrangements with biotechnology and pharmaceutical
6-K
EX-99
88n t9wly
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
i00ahlqb1gpsyg8ukrj8
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
al96rwj7vpv2 7h3
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
5tlpj4rnai x9r8xayhe
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
rbzwcjtp bg4z
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
4mbnxzy
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
a7eqwr1q8yo9i
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
424B5
d8wi8exv02kx3p69sexk
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
3qv vt0tdl0
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
kwghw3 0ss
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
3zvlqta50jz119wduksr
16 Jun 22
BioLineRx Announces Appointment of Commercial Strategy
7:05am
6-K
EX-99
5etjbz7 yp35qq
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
pni1n2 m4bv
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am